Abbott Laboratories ABT

101.29 0.22 0.22% as of 25 Sep
Market cap
$174.8B
P/E
32.8×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month

Abbott Laboratories (ABT) Gross margin

Abbott Laboratories's gross margin over the twelve months to 30 June 2026 was 56.6%, up 0.2 percentage points from fiscal 2025 (56.4%). Over the past ten years it has ranged from 54.7% (fiscal 2017) to 58.5% (fiscal 2019); the current reading is higher than 55% of that period. That is in line with the Medical Devices industry median of 56.0% and above the Healthcare sector median of 53.7%.

Gross margin, annual

Annual

Period Gross margin Change (points)
FY2025 56.4% 1.01
FY2024 55.4% 0.23
FY2023 55.2% (0.97)
FY2022 56.2% (0.82)
FY2021 57.0% 0.32
FY2020 56.7% (1.88)
FY2019 58.5% 0.08
FY2018 58.5% 3.75
FY2017 54.7% (1.69)
FY2016 56.4% (0.74)

Quarterly

Period Gross margin Change (points)
Jun 2026 57.7% 1.51
Mar 2026 56.2% (0.85)
Dec 2025 57.1% 1.69
Sep 2025 55.4% (1.08)
42 more quarters

Against its own ten years

Low 54.7% High 58.5%
Ten-year median 56.4%
Current reading's percentile 55

Gross margin against peers

Company Gross margin
EW Edwards Lifesciences Corporation compare 77.8%
BSX Boston Scientific Corporation compare 69.9%
MDT Medtronic PLC compare 65.0%
SYK Stryker Corporation compare 65.0%
DXCM DexCom, Inc. compare 62.5%
ABT Abbott Laboratories 56.6%
PHG Koninklijke Philips N.V. compare 45.9%
STE STERIS plc compare 44.4%
GEHC GE HealthCare Technologies Inc. compare 39.5%
Medical Devices industry median 56.0%
Healthcare sector median 53.7%
Market median 46.3%

What Gross margin is

Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.

Gross Profit ÷ Revenue

The full definition of Gross margin →

More on ABT